COGENT BIOSCIENCES INC

NASDAQ: COGT (Cogent Biosciences, Inc.)

Kemas kini terakhir: 8 jam lalu

27.10

-0.35 (-1.26%)

Penutupan Terdahulu 27.44
Jumlah Dagangan 1,000,287
Harga / Buku (P/B) 11.00
Julat 52 Minggu
26.36 (-2%) — 43.73 (61%)
EPS Cair (TTM) -1.97
Jumlah Hutang/Ekuiti (D/E MRQ) 7.80%
Nisbah Semasa (MRQ) 5.13
Aliran Tunai Operasi (OCF TTM) -221.77 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -125.17 M
Pulangan Atas Aset (ROA TTM) -47.45%
Pulangan Atas Ekuiti (ROE TTM) -84.04%

AISkor Stockmoo

-0.1
Nilai 30% -0.8
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info
Masa 30% -2.0
Daripada analisis teknikal AI kami terhadap carta. info NA
Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Corak Lilin info NA
Aliran bagi Tempoh Pegangan Anda info NA
Sentimen 20% 0.0
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Berita info NA
Wang Pintar 20% 3.5
Aktiviti Orang Dalam info NA
Institusi bersih +16.17% daripada saham dalam pemfailan 13F terkini: 199 pemegang menambah, 147 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -7.1% dari 31 Aug hingga 30 Oct 2026, 8.7 hari untuk tutup (FINRA). info
Keadaan pasaran dan sektor lemah.
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak tidak sependapat, jadi skor dilemahkan.
Tidak dikira dalam skor
Harga rendah berbanding purata 52 minggunya. Naik dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Tiada isyarat jelas daripada sokongan dan rintangan. info
Skor Akhir -0.13

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Cogent Biosciences, Inc. Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
COGT - - - 11.00
FOLD 5 B - - -
IGMS 71 M - - 0.760
SLGL - - - 3.80
ACAD - - - 2.34
CYTK - - - -

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 0.04%
% Dimiliki oleh Institusi 103.39%

Pemilikan

Nama Tarikh Syer Dipegang
Fairmount Funds Management Llc 30 Jun 2026 5,503,418

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 125.70%

Kedudukan Pemegang Saham
Bertambah 199 35,045,215
Berkurang 147 17,227,854
Baharu 57 13,674,570
Dijual habis 58 3,356,114

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 17,416,118 8.7
15 Oct 2026 19,661,566 8.9
30 Sep 2026 19,462,718 8.1
15 Sep 2026 18,126,492 11.8
31 Aug 2026 18,747,531 12.1
14 Aug 2026 18,411,111 8.9

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

0 Positif 1 Negatif 1 Neutral
Tarikh Jenis Butiran
06 Nov 2026 Yahoo Finance Cogent Biosciences (COGT) Faces A Valuation Test As FDA Decisions Draw Closer
Cogent Biosciences (COGT) reported widening third quarter losses and a busy regulatory calendar, posting a net loss of US$111.43 million as it approaches several FDA decisions on bezuclastinib. Cogent Biosciences’ share price has come under pressure in recent months, with the stock down about 30%…
05 Nov 2026 Yahoo Finance Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027 Cash balance of $791.1 million expected to fund operations into late 2028 WALTHAM, Mass. and BOULDER, Colo.…
27 Oct 2026 Yahoo Finance Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
WALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim 3rd Annual…
20 Oct 2026 Yahoo Finance Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
Three Regulatory Reviews, No Established Earnings Base Cogent Biosciences, Inc. (NASDAQ:COGT) has moved from proving bezuclastinib’s clinical activity to seeking regulatory approvals across distinct diseases. Its immediate valuation depends on a series of FDA decisions, starting with the November…
25 Sep 2026 Yahoo Finance Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s…
24 Sep 2026 Yahoo Finance Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased…
24 Sep 2026 Yahoo Finance Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal…
15 Sep 2026 Yahoo Finance Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027 WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent…

Isyarat Terkini corak lilin dan silang EMA

▼ Silang EMA menurun 3 sesi lalu · 12 Nov
Jangka pendek · EMA 7/20
EMA 7 hari melintas ke bawah EMA 20 hari: momentum jangka pendek berubah menurun.
▼ Silang maut 4 sesi lalu · 11 Nov
Jangka panjang · EMA 50/200
EMA 50 hari melintas ke bawah EMA 200 hari, tanda yang diperhatikan ramai bahawa arah aliran jangka panjang telah berubah menurun.

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda